Compare equities side by side
Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Today's biggest gainers and losers
Visual sector performance
Astellas Pharma is a Japan-based global pharmaceutical company specializing in urology, oncology, immunology, and transplant medicine. The company's portfolio is anchored by XTANDI (enzalutamide) for prostate cancer, which generates approximately 40% of revenue, alongside transplant immunosuppressant PROGRAF and emerging oncology assets including PADCEV (bladder cancer). Recent strong performance reflects PADCEV's commercial acceleration following expanded label approvals and geographic launches, plus pipeline progress in cell therapy and targeted oncology.
Astellas operates a focused specialty pharma model targeting high-value therapeutic areas with significant unmet need. Revenue derives from branded prescription drugs sold through specialty pharmacy channels and hospital systems globally. Pricing power stems from differentiated mechanisms of action in oncology (antibody-drug conjugates, targeted kinase inhibitors) and first-in-class positioning. The company maintains 81.7% gross margins through patent-protected products, though faces generic erosion on mature assets like PROGRAF. Co-promotion agreements (XTANDI with Pfizer, PADCEV with Seagen/Pfizer post-acquisition) provide geographic reach while sharing development costs. R&D investment focuses on cell therapy platforms, targeted protein degraders, and precision oncology to offset upcoming patent cliffs.
PADCEV revenue trajectory and market share gains in first-line bladder cancer following recent FDA approval expansions
XTANDI sales performance and competitive positioning versus next-generation androgen receptor inhibitors (ARPIs) like Johnson & Johnson's ERLEADA
Pipeline readouts for zolbetuximab (gastric cancer Phase 3), AT132 (regenerative medicine), and cell therapy programs
Regulatory approvals and label expansions in key markets (US, Europe, Japan, China) for existing and pipeline assets
Business development activity including licensing deals, acquisitions to fill post-XTANDI revenue gap, and partnership economics
Patent cliff exposure with XTANDI losing exclusivity in major markets 2027-2028, representing potential loss of $4-5B annual revenue without adequate pipeline replacement
Intensifying pricing pressure from government negotiations (US Inflation Reduction Act Medicare negotiations, Japan's biennial price cuts, European reference pricing) compressing margins on mature products
Regulatory pathway uncertainty for cell and gene therapies in pipeline, requiring manufacturing scale-up capabilities and reimbursement frameworks still evolving
Biosimilar and generic competition eroding transplant franchise as PROGRAF faces multi-source generic competition globally
XTANDI faces direct competition from Johnson & Johnson's ERLEADA and Bayer's Nubeqa in prostate cancer, with newer agents showing differentiated safety profiles potentially shifting prescribing patterns
PADCEV competitive landscape evolving rapidly with Gilead's Trodelvy, Merck's pembrolizumab combinations, and emerging antibody-drug conjugates targeting similar bladder cancer populations
Large-cap pharma competitors (Roche, Bristol Myers Squibb, Merck) possess greater financial resources for M&A and pipeline development to capture oncology market share
Chinese domestic pharmaceutical companies developing lower-cost oncology biosimilars and targeted therapies for Asian markets
Limited near-term financial distress risk given strong cash generation and moderate leverage, but capital allocation pressure to deploy cash for business development before XTANDI patent expiration
Pension obligations and retiree healthcare liabilities typical of mature Japanese corporation, though not disclosed in available data
Foreign exchange translation risk with approximately 70% of revenue generated outside Japan, exposing earnings to yen volatility
low - Pharmaceutical demand is largely non-discretionary and driven by disease incidence rather than economic conditions. Oncology and transplant medicines maintain stable prescription volumes through recessions. However, pricing pressure intensifies during economic downturns as governments and payers seek healthcare cost containment. Japan's domestic market (approximately 25-30% of revenue) shows minimal cyclicality but faces structural pricing headwinds from biennial drug price revisions.
Rising interest rates create modest headwinds through higher discount rates applied to long-duration pipeline assets in DCF valuations, compressing biotech/pharma multiples. However, Astellas maintains net cash position (Debt/Equity 0.41 is low) so financing costs are minimal. Yen depreciation versus dollar (which often correlates with US rate increases) provides translation tailwinds as US revenue converts to more yen. Primary rate sensitivity is valuation multiple compression rather than operational impact.
minimal - Business model generates strong operating cash flow ($194.5B TTM) with limited reliance on external financing. Customers are primarily government health systems, large hospital networks, and insured patients with high payment reliability. No meaningful exposure to consumer credit conditions or commercial lending markets.
growth - Recent 72.9% one-year return and 197.7% net income growth reflect strong momentum investor interest driven by PADCEV's commercial success and pipeline optionality. However, valuation metrics (2.2x P/S, 8.2x EV/EBITDA) remain reasonable versus high-growth biotech peers, attracting GARP (growth at reasonable price) investors. Institutional healthcare specialists focused on specialty pharma with durable franchises and visible product cycles. Limited dividend yield appeal compared to large-cap pharma peers given reinvestment priorities.
moderate - Beta likely in 0.8-1.1 range typical of mid-cap specialty pharma. Volatility driven by binary clinical trial readouts, regulatory decisions, and quarterly revenue surprises on key products. Less volatile than pure-play biotech due to diversified revenue base and profitability, but more volatile than mega-cap pharma with broader portfolios. Recent 37.7% three-month return suggests elevated momentum-driven volatility.